Skip to main content

Tilray (TLRY)  rose following its weaker-than-expected fourth-quarter earnings after-hours on Monday as well as early in Tuesday's session, but the stock turned red and fellow pot stocks traded mixed at midsay. 

Tilray shares were down more than 2% Tuesday afternoon. The stock had risen 3% after hours Monday as the Canadian cannabis company reported a 204% increase in year-over-year revenue to $15.5 million, and a net loss of 33 cents per share. Analysts were expecting revenue of $14.1 million and a loss of just 14 cents per share.

For the full year, revenue increased 110% to $43.1 million, which also topped Wall Street's expectation of revenue of $41.8 million.

"2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis," said CEO Brendan Kennedy.

Here is how other pot plays are performing in the wake of Tilray's results. 

Scroll to Continue

TheStreet Recommends

Cronos Group (CRON)  was down 1.86%. 

Aurora Cannabis (ACB)  rose 1.05%.

Canopy Growth (CGC)  gained 0.5%. 

Aphria (APHA)  was rising 0.7%. 

ETFMG Alternative Harvest ETF (MJ)  jumped 2%. 

Will You Have Enough Money Retire?

Want to learn about retirement planning from some of the nation's top experts? Join TheStreet's Robert "Mr. Retirement" Powell live in New York on April 6 for our Retirement Strategies Symposium. For a limited time, tickets are available for $99 for this full-day event. Check out the agenda, learn about the speakers and sign up here.